Immuno-Oncology | Specialty

Follicular Lymphoma: Outcomes with Immunotherapy

October 21st 2017

NICE Rejects Treatments for Bladder and Thyroid Cancer

October 21st 2017

The UK’s National Institute for Health and Care Excellence has issued guidelines recommending against nivolumab (Opdivo), lenvatinib (Lenvima), and sorafenib (Nexavar).

Triplet Therapy on Horizon for BRAF+ Melanoma

October 20th 2017

The combination of anti–PD-1/PD-L1 immunotherapy with BRAF plus MEK inhibitors is advancing rapidly following early promising phase results for patients with BRAF-mutant advanced melanoma.

Novel Combinations Mark Next Step for Melanoma

October 20th 2017

Immunotherapy has led a transformation for melanoma care but combinations of anti–PD-1 and CTLA-4 agents are toxic and biomarkers are not available to help personalized treatment, calling for further research into less toxic and more effective options.

Dr. Weber on Nivolumab in the Adjuvant Setting for Melanoma

October 20th 2017

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the use of nivolumab (Opdivo) in the adjuvant setting for the treatment of patients with melanoma.

Early Study Shows Promise for Genetically Modified TILs in Advanced Melanoma

October 20th 2017

Treatment with genetically engineered tumor infiltrating lymphocytes showed some signs of activity and very little added toxicity for patients with metastatic melanoma.

Dr. Harrison on the Possibility of Nivolumab Plus Ipilimumab Becoming the New IL-2

October 20th 2017

Michael R. Harrison, MD, assistant professor of medicine, Duke Cancer Institute, discusses the possibility of nivolumab (Opdivo) plus ipilimumab (Yervoy) becoming the new interleukin-2 (IL-2).

Immunotherapy Infuses New Hope Into Merkel Cell Carcinoma Care

October 20th 2017

While chemotherapy has historically been used to treat patients with Merkel cell carcinoma, immunotherapy advances have infused new hope into the treatment landscape.

Dr. Luke Discusses PD-1 Plus IDO Inhibitors in Melanoma

October 19th 2017

Jason Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the combination approach of a PD-1 antibody plus an IDO inhibitor for patients with melanoma.

Dr. Garassino Discusses Recent Pivotal Immunotherapy Findings in NSCLC

October 19th 2017

Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses some of the recent exciting results regarding immunotherapy in non-small cell lung cancer (NSCLC).

FDA Grants Priority Review to Adjuvant Nivolumab in Melanoma

October 18th 2017

The FDA has granted a priority review to a supplemental biologics license application for nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.

Dr. Zandberg on the Role of Immunotherapy in Head and Neck Cancer

October 18th 2017

Dan Zandberg, MD, assistant professor of medicine, University of Maryland School of Medicine, discusses the role of immunotherapy in head and neck cancer.

Dr. Pal on the Sequencing of Immunotherapy for Urothelial Carcinoma

October 18th 2017

Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at the City of Hope, discusses the sequencing of immunotherapy regimens in patients with urothelial carcinoma.

Immunotherapy Continues to Excite in NSCLC

October 13th 2017

Lawrence E. Feldman, MD, discusses first- and second-line therapy with checkpoint inhibitors in NSCLC, and the promise that emerging combinations could have on the field.

Novel Immunotherapy Approaches Moving Through RCC Pipeline

October 12th 2017

Matthew R. Zibelman, MD, discussed the promise of immunotherapy combinations for patients with kidney cancer.

Dr. Choueiri on the Role of Cabozantinib in RCC

October 10th 2017

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the role of cabozantinib (Cabometyx) for patients with renal cell carcinoma

Immunotherapy Agents Leading Advancements in Metastatic Bladder Cancer

October 10th 2017

The therapeutic landscape is rapidly being altered by clinical trials of immunotherapy for patients with metastatic urothelial carcinoma, but simply changing the way quality of life is monitored could provide dramatic improvements in overall survival.

Expert Discusses Continued Growth of Immunotherapy in Gastric/GEJ Cancer

October 6th 2017

Harry H. Yoon, MD discussed the promise of immunotherapy and emphasized the importance of mismatch repair deficiency testing in gastric/GEJ Cancer.

Dr. Wagstaff on the Survival Benefit of Immunotherapy in Bladder Cancer

October 6th 2017

John Wagstaff, MD, professor at Swansea University Medical School, discusses the survival benefit of immunotherapy for patients with bladder cancer.

Dr. De Santis on the Future Treatment Landscape for Bladder Cancer

October 6th 2017

Maria De Santis, MD, associate clinical professor at the University of Warwick, discusses the future treatment landscape for patients with bladder cancer.